{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-346855","form_type":"8-K","ticker":"SPRO","cik":"0001701108","company_name":"Spero Therapeutics, Inc.","filed_at":"2026-08-12T20:09:26+00:00","discovered_at":"2026-08-12T20:10:01.779898+00:00","generated_at":"2026-08-12T20:10:10.561033+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Spero Q2 net loss widens to $9.6M; FDA approves Utebzi, $105M financing extends runway","bullets":["Net loss of $9.6M ($0.16 diluted EPS) vs $1.7M loss ($0.03) in Q2 2025.","No revenue in Q2 2026 vs $14.2M in Q2 2025; all deferred revenue previously recognized.","Cash $50.8M at June 30, 2026; plus $105M royalty financing extends runway into H2 2029.","FDA approved Utebzi (tebipenem pivoxil) for cUTIs in June 2026; GSK launch expected by end of 2026.","Exclusive license with Innovent for SP001 (anti-CD40L) worldwide ex-Greater China; Phase 2 in IgG4-RD planned."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-346855","json":"https://secwatch.observer/filing/0001193125-26-346855.json","markdown":"https://secwatch.observer/filing/0001193125-26-346855.md","text":"https://secwatch.observer/filing/0001193125-26-346855.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701108/000119312526346855/0001193125-26-346855-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701108/000119312526346855/d69249d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-12T20:10:10.561033+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}